

Provider Network News

Update to Texas Medicaid and CHIP Coverage for Monoclonal Antibody Therapy

Background

Payment allowance added for some COVID-19 Monoclonal Antibody Therapy Q0222 Injection, Bebtelovimab, 175 mg claims, effective August 15, 2022.

Key Details

Pricing has been added for the COVID-19 monoclonal antibody Bebtelovimab, procedure code Q0222, effective for dates of service on or after August 15, 2022. Please note that on November 30, 2022, the U.S. Food and Drug Administration (FDA) announced that bebtelovimab is no longer authorized in any U.S. region due to lack of effectiveness against Omicron sub-variants BQ.1 and BQ.1.1. Therefore, providers may no longer administer bebtelovimab to treat COVID-19 until further notice from the FDA. Before August 15, 2022, procedure code Q0222 was not assigned a rate and processed as 'Informational,' as the drug was exclusively supplied free of charge to providers by the federal or state government. Supply of this drug was transitioned to commercial sale prior to the FDA's announcement, and providers should include the product code Q0222 on claims for dates of service from August 15, 2022, through November 29, 2022, only when the drug was purchased commercially. If the product was received from the government, the provider should only bill for the administration of the product and must not include the product code on claims for those dates of service. The purchase invoice for Bebtelovimab must be maintained in the provider's records and claims may be subject to retrospective review to verify supply source.

Claims submitted for dates of service from August 15, 2022, through November 29, 2022, that include procedure code Q0222, when the product was supplied by the federal or state government, must be voided and rebilled for the administration only. Payment received for a government-provided product is considered an overpayment and is subject to recoupment.

PCHP has until March 11, 2023, to reprocess claims, if applicable, for procedure code Q0222 with dates of service from August 15, 2022, through November 29, 2022, for appropriate payment and claims processing. Eligible providers may receive an additional payment but PCHP will not require providers to appeal the claims unless they are denied for other reasons after the claims reprocessing is complete.

Resource:

https://www.cms.gov/outreach-and-education/outreachffsprovpartprogprovider-partnership-email-archive/2022-08-11-mlnc#_Toc111030863
